Orange Book product · Generic (ANDA)
IVERMECTIN
IVERMECTIN
At a glance
Feb 26, 2026
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Feb 26, 2026
4 mo ago
Today
Pharmaceutical detail
Active ingredient
IVERMECTIN
Strength
3MG
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
ANDA 216863
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of IVERMECTIN
- 2014SOOLANTRABrand (NDA)
NDA 206255 · GALDERMA LABS LP
- 2012SKLICEBrand (NDA)
NDA 202736 · ARBOR PHARMS LLC
- 1998STROMECTOLBrand (NDA)
NDA 050742 · MERCK SHARP DOHME
- 2026IVERMECTINGeneric (ANDA)
ANDA 218509 · AJANTA PHARMA LTD
- 2026IVERMECTINGeneric (ANDA)
ANDA 216808 · E5 PHARMA
- 2025IVERMECTINGeneric (ANDA)
ANDA 218805 · EPIC PHARMA LLC
- 2025IVERMECTINGeneric (ANDA)
ANDA 215922 · RUBICON RESEARCH
- 2024IVERMECTINGeneric (ANDA)
ANDA 218324 · SENORES PHARMS
- 2022IVERMECTINGeneric (ANDA)
ANDA 215210 · ZYDUS LIFESCIENCES
- 2022IVERMECTINGeneric (ANDA)
ANDA 212485 · TEVA PHARMS USA
- 2020IVERMECTINGeneric (ANDA)
ANDA 210720 · TARO
- 2020IVERMECTINGeneric (ANDA)
ANDA 210225 · PADAGIS ISRAEL
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
